



Press Release
20 March 2017

BioEurope Spring 2017 presentation of progress in three pipeline programs

Stockholm, 20 March 2017. Nuevolution AB (publ) (NUE.ST) will participate in **BioEurope Spring** in Barcelona, 20-22 March and present updates on the company's ROR γ t inhibitor, ROR γ t agonist and BET BD1 programs.

Ton Berkien, CBO, and Søren Jensby Nielsen, Director of Biology, will present positive preliminary data from two independent mouse models of Inflammatory Bowel Disease (IBD) in the ROR γ t inhibitor program outside its partnership with Almirall. The IBD studies showed a significant effect by ameliorating colon parameters at therapeutically relevant doses of an ROR γ t inhibitor. Together with further ongoing studies these data are relevant for addressing novel indications in addition to ongoing activity already being pursued within Nuevolution's partnership with Almirall in dermatology and psoriatic arthritis.

For the Bromodomain BET BD1 program, Nuevolution will promote its previously disclosed positive data on the efficacy of NUE7770 in the pristane-induced mouse model of lupus. A complete report is now available from the two-week mouse toxicology study of NUE7770 showing no adverse effects at any doses tested, which is in contrast to significant adverse effects and high mortality observed with a control compound (non-selective BET inhibitor). Additional data on the inhibition of proliferation on 375 cancer cell lines support a benign profile of NUE7770, which is further supported by early gene expression profile data that has been generated recently. A compound co-crystal structure with BRD4-BD1, at very high resolution, demonstrates a unique binding mechanism of the BET BD1 selective compound series of Nuevolution. This important structural information will support the further optimization of Nuevolution's selective BET inhibitors.

In immuno-oncology, the activation of ROR γ t within lymphocytes infiltrated in the tumor is believed to provide a novel approach for treatment of certain cancers. New data from Nuevolution's ROR γ t agonist program will also be presented, including the validation of compound mechanism-of-action by showing a strong dose-dependent production of IL17A from stimulated mouse splenocytes.

For more information, please contact:

Ton Berkien, CBO
Phone: +45 7020 0987
Email: tob@nuevolution.com

Henrik D. Simonsen, CFO
Phone: +45 3913 0947
Email: hs@nuevolution.com





About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Monday 20 March 2017, 08.30 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

